EUVIMEDEUVIMED entdecken
Multizentrische Studie

Predicting Exacerbations in Alpha-1 Antitrypsin Deficiency Using Clinical and Pulmonary Function Tests: Portuguese EARCO Registry

Nuno Faria, Joana Gomes, Catarina Guimarães, Raquel Marçôa, Beatriz Ferraz, Maria Sucena

Respiration · 2024

DOI: 10.1159/000537759 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Respiration, 2024. Verfasst von Nuno Faria und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department, Centro Hospitalar e Universitário de Santo António, Porto, Portugal. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, Registries, Disease Progression, Respiratory Function Tests. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Exacerbations are common in individuals with alpha-1 antitrypsin deficiency (AATD)-related lung disease. This study intended to identify independent predictive factors for exacerbations in AATD using the Portuguese European Alpha-1 Research Collaboration (EARCO) registry.

Methods

This study includes patients from the Portuguese EARCO registry, a prospective multicenter cohort (NCT04180319). From October 2020 to April 2023, this registry enrolled 137 patients, 14 of whom were excluded for analysis for either missing 12 months of follow-up or baseline pulmonary function.

Results

Among the 123 AATD patients, 27 (22.0%) had at least one exacerbation in the last 12 months of follow-up. Patients with Pi*ZZ phenotype were three times more likely than the rest of the population to experience any exacerbation (32.7 vs. 14.1%, p = 0.014; OR 3.0). BODE index was significantly higher in exacerbators than in non-exacerbators (3.9 ± 2.4 vs. 1.3 ± 1.2; p < 0.001), including on multivariate analysis (p = 0.002). Similar results were found for BODEx (multivariate p < 0.001). DLCO was the only functional parameter independently associated with exacerbations (p = 0.024).

Conclusions

DLCO, BODE, and BODEx were independent predictors of exacerbations at 12 months in AATD patients. Understanding these risk factors can aid decision-making on AATD-related lung disease management and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-Antitrypsin DeficiencyRegistriesDisease ProgressionRespiratory Function TestsHumansMaleFemaleMiddle AgedPortugalProspective StudiesAgedAdultForced Expiratory Volume

Stichwörter der Autor:innen

Alpha-1 antitrypsin deficiencyDiffusing capacity of carbon monoxideExacerbationPhenotypePulmonary function tests

Autor:innen und Institutionen

  • Pulmonology Department, Centro Hospitalar e Universitário de Santo António, Porto, Portugal.
  • Pulmonology Department, Hospital Senhora da Oliveira Guimarães, Guimarães, Portugal.
  • Pulmonology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
  • Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.

Zitieren

APA

Faria, N., Gomes, J., Guimarães, C., Marçôa, R., Ferraz, B., & Sucena, M. (2024). Predicting Exacerbations in Alpha-1 Antitrypsin Deficiency Using Clinical and Pulmonary Function Tests: Portuguese EARCO Registry. Respiration. https://doi.org/10.1159/000537759

Vancouver

Faria N, Gomes J, Guimarães C, Marçôa R, Ferraz B, Sucena M. Predicting Exacerbations in Alpha-1 Antitrypsin Deficiency Using Clinical and Pulmonary Function Tests: Portuguese EARCO Registry. Respiration. 2024. doi:10.1159/000537759

BibTeX
@article{Faria2024,
  author = {Faria, Nuno and Gomes, Joana and Guimarães, Catarina and Marçôa, Raquel and Ferraz, Beatriz and Sucena, Maria},
  title = {Predicting Exacerbations in Alpha-1 Antitrypsin Deficiency Using Clinical and Pulmonary Function Tests: Portuguese EARCO Registry},
  journal = {Respiration},
  year = {2024},
  doi = {10.1159/000537759}
}
Kostenlos starten →